Embolization Treatment
Transcatheter embolization is a minimally invasive technique where catheter-directed embolic agents are delivered to stop blood vessels that are injured or bleeding or close off vessels supplying blood to a tumor.
While less invasive than open surgery, existing embolization treatments involve shortcomings requiring active management by interventional radiologists. These include:
- Failure to deeply penetrate the tumor vascular bed allowing for continued tumor blood flow
- Flow into healthy vessels leading to non-target embolization and healthy tissue injury
- Dependence on blood coagulation to stop blood flow, potentially delaying occlusion in patients with compromised blood clotting
Water-based PEG Hydrogel Technology
Embrace™ Hydrogel Embolic System (HES) consists of two low viscosity liquid precursors that polymerize intravascularly when simultaneously injected into blood vessels forming a soft, water-based PEG hydrogel, during the embolization procedure.
Before use, the precursors are mixed with commercially available iodinated contrast media enabling radiopacity. The hydrogel contains no organic solvents in its formulation. Upon delivery, the hydrogel casts out the vasculature to create a rapid and durable occlusion. The hydrogel liquifies via hydrolysis over a period of approximately 6 months, and the hydrolysis products are absorbed and cleared via renal filtration.*
Hydrogel Embolic System
Embrace Hydrogel Embolic System (HES) is a minimally-invasive, vascular embolization treatment that interventional radiologists can potentially easily deliver with immediate, complete, and persistent embolization.**
Complete and Persistent Occlusion
Predictable and Effective Embolic
Easy and Accurate Delivery
Effective at Embolizing Hypervascular Tumors
As demonstrated in the First-in-Human (FIH) study, Embrace HES was effective at embolizing malignant and benign hypervascular tumors by blocking tumor blood supply with technical success in all patients and persistent embolization as noted in imaging follow up at 30-days.*
*Data on file at Instylla.
**Ganguli S, Lareau R, Jarrett T, Soulen MC, A Water-based Liquid Embolic: Evaluation of Safety and Efficacy in a Rabbit Kidney Model, Journal of Vascular and Interventional Radiology (2021), doi: https://doi.org/10.1016/j.jvir.2021.02.018